Serum biomarkers which correlate with failure to respond to immunotherapy and tumor progression in a murine colorectal cancer model

Proteomics - Clinical Applications

Volumn 4, Issue 8-9, 2010, Pages 682-696

  Vafadar Isfahani, Baharak ^a   Laversin, Stephanie Anne Sophie ^a   Ahmad, Murrium ^a   Ball, Graham ^a   Coveney, Clare ^a   Lemetre, Christophe ^a   Kathleen Miles, Amanda ^a   Van Schalkwyk, Gerhard ^b   Rees, Robert ^a   Matharoo Ball, Balwir ^a  

^a NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

^b DERBY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cancer immunotherapy; MALDI; Serum biomarkers

Indexed keywords

DISABLED INFECTIOUS SINGLE CYCLE HERPES SIMPLEX VIRUS VECTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOGLOBIN; HEMOGLOBIN BETA 2 SUBUNIT; HEMOPEXIN; SERUM AMYLOID A; SERUM AMYLOID A 1; SERUM AMYLOID P; TUMOR MARKER; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ARTIFICIAL NEURAL NETWORK; CANCER GROWTH; CANCER IMMUNOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG TREATMENT FAILURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HERPES SIMPLEX VIRUS; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; VALIDITY; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING;

ANIMALS; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; IMMUNOTHERAPY; MALE; MICE; MICE, INBRED BALB C; NEOPLASM STAGING; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

MURINAE; MUS; SIMPLEXVIRUS;

EID: 78650448918     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.200900218     Document Type: Article

References (68)

1. Wray, C. J., Rilo, H. L., Ahmad, S. A., Colon cancer angiogenesis and antiangiogenic therapy. Expert Opin. Investig. Drugs. 2004, 130, 631-641.
2. Michener, C. M., Ardekani, A. M., Petricion, E. F., Liotta, L. A. et al., Genomics and proteomics: application of novel technology to early detection and prevention of cancer. Cancer Detect. Prev. 2002, 26, 249-255.
3. Juan, H. F., Chen, J. H., Hsu, W. T., Huang, S. C. et al., Identification of tumor-associated plasma biomarkers using proteomic techniques: from mouse to human. Proteomics 2004, 4, 2766-2775.
4. Hung, K. E., Kho, A. T., Sarracino, D., Richard, L. G. et al., Mass spectrometry-based study of the plasma proteome in a mouse intestinal tumor model. J. Proteome Res. 2006, 5, 1866-1878.
5. Culp, W. D., Neal, R., Massey, R., Egevad, L. et al., Proteomic analysis of tumor establishment and growth in the B16-F10 mouse melanoma model. J. Proteome Res. 2006, 5, 1332-1343.
6. Sandoval, J. A., Turner, K. E., Hoelz, D. J., Rescorla, F. J. et al., Serum protein profiling to identify high-risk neuroblastoma: preclinical relevance of blood-based biomarkers. J. Surg. Res. 2007, 134, 61-67.
7. Ahmad, M., Rees, R. C., McArdle, S. E., Li, G. et al., Regulation of CTL responses to MHC-restricted class I peptide of the gp70 tumour antigen by splenic parenchymal CD4+ T cells in mice failing immunotherapy with DISC-mGM-CSF. Int. J. Cancer 2005, 115, 951-959.
8. Mann, M., Hendrickson, R. C., Pandey, A., Analysis of proteins and proteomes by mass spectrometry. Annu. Rev. Biochem. 2001, 70, 437-473.
9. Brouwers, F. M., Petricoin, E. F., Ksinantova, L., Breza, J. et al., Low molecular weight proteomics information distinguishes metastatic from benign pheochromocytoma. Endocr. Relat. Cancer 2005, 12, 263-272.
10. Tirumalai, R. S., Chan, K. C., Prieto, D. A., Issaq, H. J. et al., Characterization of the low molecular weight human serum proteome. Mol. Cell. Proteomic 2003, 2, 1096-1103.
11. Ball, G., Mian, S., Holding, F., Allibone, R. O. et al., An integrated approach utilizing artificial neural networks and SELDI mass spectrometry for the classification of human tumours and rapid identification of potential biomarkers. Bioinformatics 2002, 18, 395-404.
12. Matharoo-Ball, B., Ratcliffe, L., Lancashire, L., Ugurel, S. et al., Diagnostic biomarkers differentiating metastatic melanoma patients from healthy controls identified by an integrated MALDI-TOF mass spectrometry/bioinformatic approach. Proteomics Clin. Appl. 2007, 1, 605-620.
13. de Noo, M. E., Mertens, B. J., Ozalp, A., Bladergroen, M. R. et al., Detection of colorectal cancer using MALDI-TOF serum protein profiling. Eur. J. Cancer 2006, 42, 1068-1076.
14. Lancashire, L. J., Mian, S., Ellis, I. O., Rees, R. C. et al., Current developments in the analysis of proteomic data: Artificial neural network data mining techniques for the identification of proteomic biomarkers related to breast cancer. Curr. Proteomics 2005, 2, 15-29.
15. Veenstra, T. D., Prieto, D. A., Conrads, T. P., Proteomic patterns for early cancer detection. Drug Discov. Today 2004, 9, 889-897.
16. Pastwa, E., Somiari, S. B., Czyz, M., Somiari, R. I., Proteomics in human cancer research. Proteomics Clin. App. 2007, 1, 4-17.
17. Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. J. et al., Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359, 572-577.
18. Villanueva, J., Philip, J., Chaparro, C. A., Li, Y. et al., Correcting common errors in identifying cancer-specific serum peptide signatures. J. Proteome Res. 2005, 4, 1060-1072.
19. Ransohoff, D. F., Lessons from controversy: ovarian cancer screening and serum proteomics. J. Natl. Cancer Inst. 2005, 97, 315-319.
20. Baggerly, K. A., Morris, J. S., Coombes, K. R., Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 2004, 20, 777-785.
21. Diamandis, E. P., van der Merwe, D. E., Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. Clin. Cancer Res. 2005, 11, 963-965.
22. Smith, F. M., Gallagher, W. M., Fox, E., Stephens, R. B. et al., Combination of SELDI-TOF-MS data mining provides early-stage response prediction for rectal tumours undergoing multimodel neoadjuvant therapy. Ann. Surg. 2007, 245, 259-266.
23. Bedrosian, I., Rodriguez-Bigas, M. A., Feig, B., Hunt, K. K. et al., Predicting the node-negative mesorectum after preoperative chemoradiation for locally advanced rectal carcinoma. J. Gastrointest. Surg. 2004, 8, 56-62.
24. Smith, F. M., Stephens, R. B., Kennedy, M. J., Reynolds, J. V., p53 abnormalities and outcomes in colorectal cancer: a systematic review. Br. J. Cancer 2005, 92, 1813.
25. Smith, F. M., Reynolds, J. V., Miller, N., Stephens, R. B. et al., Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. Eur. J. Surg. Oncol. 2006, 32, 55-64.
26. Diamandis, E. P., Serum proteomic profiling by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry for cancer diagnosis: next steps. Cancer Res. 2006, 66, 5540-5541.
27. Lancashire, L. J., Rees, R. C., Ball, G. R., Identification of gene transcript signatures predictive for estrogen receptor and lymph node status using a stepwise forward selection artificial neural network modelling approach. Artif. Intell. Med. 2008, 43, 99-111.
28. Lin, S. Y., Chen, Y. Y., Fan, Y. Y., Lin, C. W. et al., Precise mapping of increased sialylation pattern and the expression of acute phase proteins accompanying murine tumor progression in BALB/c mouse by integrated sera proteomics and glycomics. J. Proteome Res. 2008, 8, 3293-3303.
29. Cho, W. C., Nasopharyngeal carcinoma: molecular biomarker discovery and progress. Mol. Cancer 2007, 6, 1.
30. Kaneti, J., Winikoff, Y., Zimlichman, S., Shainkin-Kestenbaum, R., Importance of serum amyloid A (SAA) level in monitoring disease activity and response to therapy in patients with prostate cancer. Urol. Res. 1984, 12, 239-241.
31. Müller, T. F., Trösch, F., Ebel, H., Grüssner, R. W. et al., Pancreas-specific protein (PASP), serum amyloid A (SAA), and neopterin (NEOP) in the diagnosis of rejection after simultaneous pancreas and kidney transplantation. Transpl. Int. 1997, 10, 185-191.
32. Gutfeld, O., Prus, D., Ackerman, Z., Dishon, S. et al., Expression of serum amyloid A, in normal, dysplastic, and neoplastic human colonic mucosa: implication for a role in colonic tumorigenesis. J. Histochem. Cytochem. 2006, 54, 63-73.
33. Cocco, E., Bellone, S., El-Sahwi, K., Cargnelutti, M. et al., Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer. Br. J. Cancer 2009, 101, 335-341.
34. Ghezzi, P., Bertini, R., Bianchi, M., Erroi, A. et al., Serum amyloid A induction in tumor-bearing mice: evidence for a tumor-derived mediator. Int. J. Immunopathol. Pharmacol. 1993, 6, 169-186.
35. Steel, D. M., Whitehead, A. S., The major acute phase reactants: C-reactive protein serum amyloid P component and serum amyloid A protein. Immunol. Today 1994, 15, 81-88
36. Niederau, C., Backmerhoff, F., Schumacher, B., Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis. Hepatogastroenterology 1997, 44, 90-107.
37. Keshavarzian, A., Fusunyan, R. D., Jacyno, M., Winship, D. et al., Increased interleukin-8 (IL-8) in rectal dialysate from patients with ulcerative colitis: evidence for a biological role for IL-8 in inflammation of the colon. Am. J. Gastroenterol. 1999, 94, 704-712.
38. Bachwich, D. R., Lichtenstein, G. R., Traber, P. G., Cancer in inflammatory bowel disease. Med. Clin. North Am. 1994, 78, 1399-1412.
39. Rhodes, J. M., Campbell, B. J., Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. Trends Mol. Med. 2002, 8, 10-16.
40. Farrell, R. J., Peppercorn, M. A., Ulcerative colitis. Lancet 2002, 359, 331-340.
41. Hao, C. Y., Moore, D. H., Wong, P., Bennington, J. L. et al., Alteration of gene expression in macroscopically normal colonic mucosa from individuals with a family history of sporadic colon cancer. Clin. Cancer Res. 2005, 11, 1400-1407.
42. Migita, K., Kawabe, Y., Tominaga, M., Origuchi, T. et al., Serum amyloid A protein induces production of matrix metalloproteinases by human synovial fibroblasts. Lab. Invest. 1998, 78, 535-539.
43. O_Hara, R., Murphy, E. P., Whitehead, A. S., FitzGerald, O. et al., Local expression of the serum amyloid A and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis. Arthritis Rheum. 2004, 50, 1788-1799.
44. Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W. et al., A model for p53-induced apoptosis. Nature 1997, 389, 300-305.
45. Balkwill, F., Mantovani, A., Inflammation and cancer: back to Virchow? Lancet 2001, 357, 539-545.
46. Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R. et al., NF-kB functions as a tumor promoter in inflammation-associated cancer. Nature 2004, 431, 461-466.
47. Clevers, H., At the crossroads of inflammation and cancer. Cell 2004, 118, 671-674.
48. Badolato, R., Wang, J. M., Murphy, W. J., Lloyd, A. R. et al., Serum amyloid A is a chemoattractant: induction of migration, adhesion and tissue infiltration of monocytes and polymorphonuclear leukocytes. J. Exp. Med. 1994, 180, 203-209.
49. Xu, L., Badolato, R., Murphy, W. J., Longo, D. L. et al., A novel biologic function of serum amyloid A. Induction of T lymphocyte migration and adhesion. J. Immunol. 1995, 155, 1184-1190.
50. Patel, H., Fellowes, R., Coade, S., Woo, P., Human serum amyloid A has cytokine-like properties. Scan. J. Immunol. 1998, 48, 410-418.
51. Furlaneto, C. J., Campa, A., A novel function of serum amyloid A: a potent stimulus for the release of tumor necrosis factor-alpha, interleukin-1beta, and interleukin-8 by human blood neutrophil. Biochem. Biophys. Res. Commun. 2000, 268, 405-408.
52. Noursadeghi, M., Bickerstaff, M. C., Gallimore, J. R., Herbert, J. et al., Role of serum amyloid P component in bacterial infection: protection of the host or protection of pathogen. Proc. Natl. Acad. Sci. USA 2000, 97, 1458-1459.
53. Stewart, C. R., Haw, A., Lopez, R., McDonald, T. O. et al., Serum amyloid P colocalizes with apolipoproteins in human atheroma: functional implications. J. Lipid Res. 2007, 48, 2162-2171.
54. Zahedi, K., Whitehead, A. S., Regulation of mouse serum amyloid P gene expression by cytokines in vitro. Biochim. Biophys. Acta 1993, 1176, 162-168.
55. Tolosano, E., Altruda, F., Hemopexin: structure, function, and regulation. DNA Cell Biol. 2002, 21, 297-306.
56. Delanghe, J. R., Langlois, M. R., Hemopexin: a review of biological aspects and the role in laboratory medicine. Clin. Chim. Acta 2001, 312, 13-23.
57. Römpp, A., Dekker, L., Taban, I., Jenster, G. et al., Identification of leptomeningeal metastasis-related proteins in cerebrospinal fluid of patients with breast cancer by a combination of MALDI-TOF, MALDI-FTICR and nanoLC-FTICR MS. Proteomics 2007, 7, 474-481.
58. Smith, A., Eskew, J. D., Borza, C. M., Pendrak, M. et al., Role of heme-hemopexin in human T-lymphocyte proliferation. Exp. Cell Res. 1997, 232, 246-254.
59. Schottenfeld, D., Beebe-Dimmer, J., Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J. Clin. 2006, 56, 69-83.
60. Coussens, L. M., Werb, Z., Inflammation and cancer. Nature 2002, 420, 860-867.
61. Malle, E., Sodin-Semrl, S., Kovacevic, A., Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell Mol. Life Sci. 2009, 66, 9-26.
62. Parle-McDermott, A., McWilliam, P., Tighe, O., Dunican, D. et al., Serial analysis of gene expression identifies putative metastasis-associated transcripts in colon tumour cell lines. Br. J. Cancer 2000, 83, 725-728.
63. Hao, C. Y., Moore, D. H., Wong, P., Bennington, J. L. et al., Alteration of gene expression in macroscopically normal colonic mucosa from individuals witha family history of sporadic colon cancer. Clin. Cancer Res. 2005, 11, 1400-1407.
64. Nishie, A., Masuda, K., Otsubo, M., Migita, T. et al., High expression of the Cap43 gene in infiltrating macrophages of human renal cell carcinomas. Clin. Cancer Res. 2001, 7, 2145-2151.
65. Kosari, F., Parker, A. S., Kube, D. M., Lohse, C. M., Leibovich, B. C. et al., Clear cell renal cell carcinoma: gene analyses identify a potential signature for tumor aggressiveness. Clin. Cancer Res. 2005, 11, 5128-5139.
66. Vreugdenhil, A. C., Dentener, M. A., Snoek, A. M., Greve, J. W. et al., Lipopolysaccharide binding protein and serum amyloid A secretion by human intestinal epithelial cells during the acute phase response. J. Immunol. 1999, 163, 2792-2798.
67. Liang, L., Qu, L., Ding, Y., Protein and mRNA characterization in human colorectal carcinoma cell lines with different metastatic potentials. Cancer Invest. 2007, 25, 427-434.
68. Kovacevic, A., Hammer, A., Stadelmeyer, E., Windischhofer, W. et al., Expression of serum amyloid A transcripts in human bone tissues, differentiated osteoblast-like stem cells and human osteosarcoma cell lines. J. Cell. Biochem. 2008, 103, 994-1004.